60 Degrees Pharmaceuticals Announces Enrollment Of Minimum 24 Patients Triggering Interim Analysis In Severe Babesiosis Tafenoquine Study, Results By October 6

Benzinga Newsdesk www.benzinga.com Neutral 82.7%

Neg 0% Neu 82.7% Pos 0%

Comments

No comments yet. Be the first!